Abstract

N/A

Highlights

  • Roflumilast cream, a phosphodiesterase-4 (PDE-4) inhibitor that is more potent than other PDE-4 inhibitors,[1] is under investigation as a once-daily, nonsteroidal, topical treatment for psoriasis

  • Baseline is defined as the last observation prior to the first dose of roflumilast cream in either the ARQ-151-201 or ARQ-151-202 study

  • Among all rollover groups, IGA success was between 33% and 37%, and exceeded that observed among these patients at Week 12 of the parent study

Read more

Summary

INTRODUCTION

Topical treatment options for chronic plaque psoriasis lack products that are safe with long-term usage, are well tolerated, and are used as single agents over the entire body. Roflumilast cream, a phosphodiesterase-4 (PDE-4) inhibitor that is more potent than other PDE-4 inhibitors,[1] is under investigation as a once-daily, nonsteroidal, topical treatment for psoriasis. In a phase 2b randomized, double-blind, 12-week trial of 331 adults with chronic plaque psoriasis, roflumilast cream once daily was found to be superior to vehicle cream and was well tolerated[2]. This multicenter, open-label, 52-week study was conducted to assess long-term safety of roflumilast 0.3% cream in patients with chronic plaque psoriasis. ELIGIBILITY Diagnosis of at least mild plaque psoriasis for at least 6 months Age ≥18 years 2-25% BSA*.

RESULTS
CONCLUSIONS
DISCLOSURES

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.